1. Home
  2. OBIO vs PFX Comparison

OBIO vs PFX Comparison

Compare OBIO & PFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBIO
  • PFX
  • Stock Information
  • Founded
  • OBIO 2017
  • PFX 2010
  • Country
  • OBIO United States
  • PFX United States
  • Employees
  • OBIO N/A
  • PFX N/A
  • Industry
  • OBIO Medicinal Chemicals and Botanical Products
  • PFX Finance: Consumer Services
  • Sector
  • OBIO Health Care
  • PFX Finance
  • Exchange
  • OBIO Nasdaq
  • PFX Nasdaq
  • Market Cap
  • OBIO 118.8M
  • PFX 98.5M
  • IPO Year
  • OBIO N/A
  • PFX N/A
  • Fundamental
  • Price
  • OBIO $2.57
  • PFX $49.25
  • Analyst Decision
  • OBIO Strong Buy
  • PFX
  • Analyst Count
  • OBIO 4
  • PFX 0
  • Target Price
  • OBIO $14.00
  • PFX N/A
  • AVG Volume (30 Days)
  • OBIO 403.6K
  • PFX 596.0
  • Earning Date
  • OBIO 08-12-2025
  • PFX 08-06-2025
  • Dividend Yield
  • OBIO N/A
  • PFX 2.90%
  • EPS Growth
  • OBIO N/A
  • PFX N/A
  • EPS
  • OBIO N/A
  • PFX 3.06
  • Revenue
  • OBIO $2,944,000.00
  • PFX $23,958,590.00
  • Revenue This Year
  • OBIO $20.47
  • PFX $10.51
  • Revenue Next Year
  • OBIO $11.45
  • PFX N/A
  • P/E Ratio
  • OBIO N/A
  • PFX $16.10
  • Revenue Growth
  • OBIO 41.61
  • PFX 7.47
  • 52 Week Low
  • OBIO $2.37
  • PFX $44.56
  • 52 Week High
  • OBIO $7.04
  • PFX $57.40
  • Technical
  • Relative Strength Index (RSI)
  • OBIO 40.46
  • PFX 46.04
  • Support Level
  • OBIO $2.50
  • PFX $49.25
  • Resistance Level
  • OBIO $2.75
  • PFX $50.35
  • Average True Range (ATR)
  • OBIO 0.18
  • PFX 0.20
  • MACD
  • OBIO -0.03
  • PFX -0.05
  • Stochastic Oscillator
  • OBIO 11.47
  • PFX 26.47

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

About PFX PhenixFIN Corporation

PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.

Share on Social Networks: